Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Allele specificity of gamma interferon responses to the carboxyl-terminal region of Plasmodium falciparum merozoite surface protein 1 by Kenyan adults with naturally acquired immunity to malaria.

Spring MD, Chelimo K, Tisch DJ, Sumba PO, Rochford R, Long CA, Kazura JW, Moormann AM.

Infect Immun. 2010 Oct;78(10):4431-41. doi: 10.1128/IAI.00415-10. Epub 2010 Aug 9.

2.

Longevity of Genotype-Specific Immune Responses to Plasmodium falciparum Merozoite Surface Protein 1 in Kenyan Children from Regions of Different Malaria Transmission Intensity.

Bowman NM, Juliano JJ, Snider CJ, Kharabora O, Meshnick SR, Vulule J, John CC, Moormann AM.

Am J Trop Med Hyg. 2016 Sep 7;95(3):580-7. doi: 10.4269/ajtmh.15-0710. Epub 2016 Aug 1.

3.

Humoral and cellular immunity to Plasmodium falciparum merozoite surface protein 1 and protection from infection with blood-stage parasites.

Moormann AM, Sumba PO, Chelimo K, Fang H, Tisch DJ, Dent AE, John CC, Long CA, Vulule J, Kazura JW.

J Infect Dis. 2013 Jul;208(1):149-58. doi: 10.1093/infdis/jit134. Epub 2013 Mar 28.

4.

Ex vivo cytokine and memory T cell responses to the 42-kDa fragment of Plasmodium falciparum merozoite surface protein-1 in vaccinated volunteers.

Huaman MC, Martin LB, Malkin E, Narum DL, Miller LH, Mahanty S, Long CA.

J Immunol. 2008 Feb 1;180(3):1451-61.

5.

Temporal stability of naturally acquired immunity to Merozoite Surface Protein-1 in Kenyan adults.

Dent AE, Chelimo K, Sumba PO, Spring MD, Crabb BS, Moormann AM, Tisch DJ, Kazura JW.

Malar J. 2009 Jul 16;8:162. doi: 10.1186/1475-2875-8-162.

6.

Age-related differences in naturally acquired T cell memory to Plasmodium falciparum merozoite surface protein 1.

Chelimo K, Embury PB, Sumba PO, Vulule J, Ofulla AV, Long C, Kazura JW, Moormann AM.

PLoS One. 2011;6(9):e24852. doi: 10.1371/journal.pone.0024852. Epub 2011 Sep 16.

7.

Shift in epitope dominance of IgM and IgG responses to Plasmodium falciparum MSP1 block 4.

Chang SP, Kayatani AK, Terrientes ZI, Herrera S, Leke RG, Taylor DW.

Malar J. 2010 Jan 13;9:14. doi: 10.1186/1475-2875-9-14.

8.

Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01.

Otsyula N, Angov E, Bergmann-Leitner E, Koech M, Khan F, Bennett J, Otieno L, Cummings J, Andagalu B, Tosh D, Waitumbi J, Richie N, Shi M, Miller L, Otieno W, Otieno GA, Ware L, House B, Godeaux O, Dubois MC, Ogutu B, Ballou WR, Soisson L, Diggs C, Cohen J, Polhemus M, Heppner DG Jr, Ockenhouse CF, Spring MD.

Malar J. 2013 Jan 23;12:29. doi: 10.1186/1475-2875-12-29.

9.
10.
12.

Impact of pre-existing MSP1(42)-allele specific immunity on potency of an erythrocytic Plasmodium falciparum vaccine.

Bergmann-Leitner ES, Duncan EH, Mease RM, Angov E.

Malar J. 2012 Sep 7;11:315. doi: 10.1186/1475-2875-11-315.

14.

Assessment of immune interference, antagonism, and diversion following human immunization with biallelic blood-stage malaria viral-vectored vaccines and controlled malaria infection.

Elias SC, Collins KA, Halstead FD, Choudhary P, Bliss CM, Ewer KJ, Sheehy SH, Duncan CJ, Biswas S, Hill AV, Draper SJ.

J Immunol. 2013 Feb 1;190(3):1135-47. doi: 10.4049/jimmunol.1201455. Epub 2013 Jan 4.

15.

Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium.

Bargieri DY, Leite JA, Lopes SC, Sbrogio-Almeida ME, Braga CJ, Ferreira LC, Soares IS, Costa FT, Rodrigues MM.

Vaccine. 2010 Apr 1;28(16):2818-26. doi: 10.1016/j.vaccine.2010.02.004. Epub 2010 Feb 17.

PMID:
20170765
16.

Plasmodium falciparum merozoite surface protein 1 (MSP1): genotyping and humoral responses to allele-specific variants.

Ekala MT, Jouin H, Lekoulou F, Issifou S, Mercereau-Puijalon O, Ntoumi F.

Acta Trop. 2002 Jan;81(1):33-46.

PMID:
11755430
17.

A DNA vaccine encoding the 42 kDa C-terminus of merozoite surface protein 1 of Plasmodium falciparum induces antibody, interferon-gamma and cytotoxic T cell responses in rhesus monkeys: immuno-stimulatory effects of granulocyte macrophage-colony stimulating factor.

Kumar S, Villinger F, Oakley M, Aguiar JC, Jones TR, Hedstrom RC, Gowda K, Chute J, Stowers A, Kaslow DC, Thomas EK, Tine J, Klinman D, Hoffman SL, Weiss WW.

Immunol Lett. 2002 Apr 1;81(1):13-24.

PMID:
11841841
18.

The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites.

Darko CA, Angov E, Collins WE, Bergmann-Leitner ES, Girouard AS, Hitt SL, McBride JS, Diggs CL, Holder AA, Long CA, Barnwell JW, Lyon JA.

Infect Immun. 2005 Jan;73(1):287-97.

19.

Human leukocyte antigen class II alleles influence levels of antibodies to the Plasmodium falciparum asexual-stage apical membrane antigen 1 but not to merozoite surface antigen 2 and merozoite surface protein 1.

Johnson AH, Leke RG, Mendell NR, Shon D, Suh YJ, Bomba-Nkolo D, Tchinda V, Kouontchou S, Thuita LW, van der Wel AM, Thomas A, Stowers A, Saul A, Zhou A, Taylor DW, Quakyi IA.

Infect Immun. 2004 May;72(5):2762-71.

20.

Fine specificity of neonatal lymphocytes to an abundant malaria blood-stage antigen: epitope mapping of Plasmodium falciparum MSP1(33).

Malhotra I, Wamachi AN, Mungai PL, Mzungu E, Koech D, Muchiri E, Moormann AM, King CL.

J Immunol. 2008 Mar 1;180(5):3383-90.

Supplemental Content

Support Center